Challenges and opportunities of next-generation sequencing: A cytopathologist's perspective

Cytopathology

Volumn 26, Issue 5, 2015, Pages 271-283

  Vigliar, E ^a   Malapelle, U ^a   de Luca, C ^a   Bellevicine, C ^a   Troncone, G ^a  

^a UNIVERSITY OF NAPLES FEDERICO II   (Italy)

Author keywords

454 NGS; Cytology; Fine needle aspiration; Illumina; Ion Torrent; Molecular Cytopathology; Next generation sequencing; Targeted therapy

Indexed keywords

DNA; BIOLOGICAL MARKER;

CYTOPATHOLOGIST; CYTOPATHOLOGY; DNA SEQUENCE; FALSE NEGATIVE RESULT; FOLLOW UP; GENE AMPLIFICATION; GENE MUTATION; GENETIC ANALYSIS; HUMAN; HYBRIDIZATION; LASER CAPTURE MICRODISSECTION; NEXT GENERATION SEQUENCING; PATHOLOGIST; PRIORITY JOURNAL; PYROSEQUENCING; REVIEW; SMEAR; BIOLOGY; GENETICS; HIGH THROUGHPUT SEQUENCING; METABOLISM; MOLECULAR PATHOLOGY; MUTATION; PROCEDURES;

BIOMARKERS; COMPUTATIONAL BIOLOGY; HIGH-THROUGHPUT NUCLEOTIDE SEQUENCING; HUMANS; MUTATION; PATHOLOGY, MOLECULAR;

EID: 84942084816     PISSN: 09565507     EISSN: 13652303     Source Type: Journal    
DOI: 10.1111/cyt.12265     Document Type: Review

References (56)

1. Bellevicine C, Vita GD, Malapelle U, Troncone G. Applications and limitations of oncogene mutation testing in clinical cytopathology. Semin Diagn Pathol 2013;30:284-97.
2. Troncone G, Cozzolino I, Fedele M, Malapelle U, Palombini L. Preparation of thyroid FNA material for routine cytology and BRAF testing: a validation study. Diagn Cytopathol 2010;38:172-6.
3. Clark DP. Molecular diagnostics on thyroid fine-needle aspirations: the pathway to value creation. Cancer Cytopathol 2010;118:14-6.
4. de Biase D, Visani M, Baccarini P et al. Next generation sequencing improves the accuracy of KRAS mutation analysis in endoscopic ultrasound fine needle aspiration pancreatic lesions. PLoS ONE 2014;9:e87651.
5. Bellevicine C, Malapelle U, de Luca C et al. EGFR analysis: current evidence and future directions. Diagn Cytopathol 2014;42:984-92.
6. Malapelle U, Bellevicine C, Zeppa P, Palombini L, Troncone G. Cytology-based gene mutation tests to predict response to anti-epidermal growth factor receptor therapy: a review. Diagn Cytopathol 2011;39:703-10.
7. Clark DP. Seize the opportunity: underutilization of fine-needle aspiration biopsy to inform targeted cancer therapy decisions. Cancer Cytopathol 2009;117:289-97.
8. Idowu MO. Epidermal growth factor receptor in lung cancer: the amazing interplay of molecular testing and cytopathology. Cancer Cytopathol 2013;121:540-3.
9. Sanger F, Coulson AR. A rapid method for determining sequences in DNA by primed synthesis with DNA polymerase. J Mol Biol 1975;94:441-8.
10. Ronaghi M. Pyrosequencing for SNP genotyping. Methods Mol Biol 2003;212:189-95.
11. Smouse JH, Cibas ES, Janne PA et al. EGFR mutations are detected comparably in cytologic and surgical pathology specimens of nonsmall cell lung cancer. Cancer Cytopathol 2009;117:67-72.
12. Malapelle U, Vigliar E, Sgariglia R et al. Ion Torrent next-generation sequencing for routine identification of clinically relevant mutations in colorectal cancer patients. J Clin Pathol 2015;68:64-8.
13. Rothberg JM, Leamon JH. The development and impact of 454 sequencing. Nat Biotechnol 2008;26:1117-24.
14. Pant S, Weiner R, Marton MJ. Navigating the rapids: the development of regulated next-generation sequencing-based clinical trial assays and companion diagnostics. Front Oncol 2014;4:78.
15. Salto-Tellez M, de Castro DG. Next generation sequencing: a change of paradigm in molecular diagnostic validation. J Pathol 2014;234:5-10.
16. Loman NJ, Misra RV, Dallman TJ et al. Performance comparison of benchtop high-throughput sequencing platforms. Nat Biotechnol 2012;30:434-9.
17. Mardis ER. Next-generation sequencing platforms. Annu Rev Anal Chem (Palo Alto Calif) 2013;6:287-303.
18. Beadling C, Neff TL, Heinrich MC et al. Combining highly multiplexed PCR with semiconductor-based sequencing for rapid cancer genotyping. J Mol Diagn 2013;15:171-6.
19. Rothberg JM, Hinz W, Rearick TM et al. An integrated semiconductor device enabling non-optical genome sequencing. Nature 2011;475:348-52.
20. Merriman B, Ion Torrent R, Team D, Rothberg JM. Progress in ion torrent semiconductor chip based sequencing. Electrophoresis 2012;33:3397-417.
21. Bentley DR, Balasubramanian S, Swerdlow HP et al. Accurate whole human genome sequencing using reversible terminator chemistry. Nature 2008;456:53-9.
22. Tsongalis GJ, Peterson JD, de Abreu FB et al. Routine use of the Ion Torrent AmpliSeq Cancer Hotspot Panel for identification of clinically actionable somatic mutations. Clin Chem Lab Med 2014;52:707-14.
23. Gargis AS, Kalman L, Berry MW et al. Assuring the quality of next-generation sequencing in clinical laboratory practice. Nat Biotechnol 2012;30:1033-6.
24. Scarpa A, Sikora K, Fassan M et al. Molecular typing of lung adenocarcinoma on cytological samples using a multigene next generation sequencing panel. PLoS ONE 2013;8:e80478.
25. Young G, Wang K, He J et al. Clinical next-generation sequencing successfully applied to fine-needle aspirations of pulmonary and pancreatic neoplasms. Cancer Cytopathol 2013;121:688-94.
26. Le Mercier M, D'Haene N, De Neve N et al. Next-generation sequencing improves the diagnosis of thyroid FNA specimens with indeterminate cytology. Histopathology 2015;66:215-24.
27. Gleeson FC, Kipp BR, Levy MJ et al. Lung cancer adrenal gland metastasis: optimal fine-needle aspirate and touch preparation smear cellularity characteristics for successful theranostic next-generation sequencing. Cancer Cytopathol 2014;122:822-32.
28. Gleeson FC, Kipp BR, Kerr SE et al. Kinase genotype analysis of gastric gastrointestinal stromal tumor cytology samples using targeted next-generation sequencing. Clin Gastroenterol Hepatol 2015;13:202-6.
29. Karnes HE, Duncavage EJ, Bernadt CT. Targeted next-generation sequencing using fine-needle aspirates from adenocarcinomas of the lung. Cancer Cytopathol 2014;122:104-13.
30. Kanagal-Shamanna R, Portier BP, Singh RR et al. Next-generation sequencing-based multi-gene mutation profiling of solid tumors using fine needle aspiration samples: promises and challenges for routine clinical diagnostics. Mod Pathol 2014;27:314-27.
31. Lin MT, Mosier SL, Thiess M et al. Clinical validation of KRAS, BRAF, and EGFR mutation detection using next-generation sequencing. Am J Clin Pathol 2014;141:856-66.
32. McCall CM, Mosier S, Thiess M et al. False positives in multiplex PCR-based next-generation sequencing have unique signatures. J Mol Diagn 2014;16:541-9.
33. Le Mercier M, D'Haene N, De Neve N et al. Next-generation sequencing improves the diagnosis of thyroid FNA specimens with indeterminate cytology. Histopathology 2015;66:215-24.
34. Nikiforova MN, Wald AI, Roy S, Durso MB, Nikiforov YE. Targeted next-generation sequencing panel (ThyroSeq) for detection of mutations in thyroid cancer. J Clin Endocrinol Metab 2013;98:E1852-60.
35. Xuan J, Yu Y, Qing T, Guo L, Shi L. Next-generation sequencing in the clinic: promises and challenges. Cancer Lett 2013;340:284-95.
36. de Biase D, Visani M, Malapelle U et al. Next-generation sequencing of lung cancer EGFR exons 18-21 allows effective molecular diagnosis of small routine samples (cytology and biopsy). PLoS ONE 2013;8:e83607.
37. Buttitta F, Felicioni L, Del Grammastro M et al. Effective assessment of egfr mutation status in bronchoalveolar lavage and pleural fluids by next-generation sequencing. Clin Cancer Res 2013;19:691-8.
38. Moskalev EA, Stoehr R, Rieker R et al. Increased detection rates of EGFR and KRAS mutations in NSCLC specimens with low tumour cell content by 454 deep sequencing. Virchows Arch 2013;462:409-19.
39. Kubota Y, Kawakami H, Natsuizaka M et al. CTNNB1 mutational analysis of solid-pseudopapillary neoplasms of the pancreas using endoscopic ultrasound-guided fine-needle aspiration and next-generation deep sequencing. J Gastroenterol 2015;50:203-10.
40. Malapelle U, Carlomagno C, Salatiello M et al. KRAS mutation detection by high-resolution melting analysis significantly predicts clinical benefit of cetuximab in metastatic colorectal cancer. Br J Cancer 2012;107:626-31.
41. Ohori NP, Singhal R, Nikiforova MN et al. BRAF mutation detection in indeterminate thyroid cytology specimens: underlying cytologic, molecular, and pathologic characteristics of papillary thyroid carcinoma. Cancer Cytopathol 2013;121:197-205.
42. Cancer Genome Atlas Research Network. Integrated genomic characterization of papillary thyroid carcinoma. Cell 2014;159:676-90.
43. Kelly LM, Barila G, Liu P et al. Identification of the transforming STRN-ALK fusion as a potential therapeutic target in the aggressive forms of thyroid cancer. Proc Natl Acad Sci USA 2014;111:4233-8.
44. Nikiforov YE, Carty SE, Chiosea SI et al. Highly accurate diagnosis of cancer in thyroid nodules with follicular neoplasm/suspicious for a follicular neoplasm cytology by ThyroSeq v2 next-generation sequencing assay. Cancer 2014;120:3627-34.
45. Hadd AG, Houghton J, Choudhary A et al. Targeted, high-depth, next-generation sequencing of cancer genes in formalin-fixed, paraffin-embedded and fine-needle aspiration tumor specimens. J Mol Diagn 2013;15:234-47.
46. Gailey MP, Stence AA, Jensen CS, Ma D. Multiplatform comparison of molecular oncology tests performed on cytology specimens and formalin-fixed, paraffin-embedded tissue. Cancer Cytopathol 2015;123:30-9.
47. Kinde I, Bettegowda C, Wang Y et al. Evaluation of DNA from the Papanicolaou test to detect ovarian and endometrial cancers. Sci Transl Med 2013;5:167ra4.
48. Lindeman NI, Cagle PT, Beasley MB et al. Molecular testing guideline for selection of lung cancer patients for EGFR and ALK tyrosine kinase inhibitors: guideline from the College of American Pathologists, International Association for the Study of Lung Cancer, and Association for Molecular Pathology. Arch Pathol Lab Med 2013;137:828-60.
49. Beadling C, Heinrich MC, Warrick A et al. Multiplex mutation screening by mass spectrometry evaluation of 820 cases from a personalized cancer medicine registry. J Mol Diagn 2011;13:504-13.
50. Magdaleno SM, Cheng A, Petraroli R et al. Abstract 3575: The OncoNetwork Consortium: a global collaborative research study on the development and verification of an Ion AmpliSeq RNA gene lung fusion panel. Cancer Res 2014;74(19 Suppl):3575.
51. Vigliar E, Malapelle U, Bellevicine C, de Luca C, Troncone G. Outsourcing cytological samples to a referral laboratory for EGFR testing in non-small cell lung cancer: does theory meet practice? Cytopathology 2014. doi: 10.1111/cyt.12221
52. Tripathy D, Harnden K, Blackwell K, Robson M. Next generation sequencing and tumor mutation profiling: are we ready for routine use in the oncology clinic? BMC Med 2014;12:140.
53. Bedard PL, Hansen AR, Ratain MJ, Siu LL. Tumour heterogeneity in the clinic. Nature 2013;501:355-64.
54. Marchetti A, Del Grammastro M, Filice G et al. Complex mutations & subpopulations of deletions at exon 19 of EGFR in NSCLC revealed by next generation sequencing: potential clinical implications. PLoS ONE 2012;7:e42164.
55. Malapelle U, Bellevicine C, de Luca C et al. EGFR mutations detected on cytology samples by a centralized laboratory reliably predict response to gefitinib in non small cell lung cancer patients. Cancer Cytopathol 2013;121:552-60.
56. Ohori NP, Nikiforova MN, Schoedel KE et al. Contribution of molecular testing to thyroid fine-needle aspiration cytology of "follicular lesion of undetermined significance/atypia of undetermined significance". Cancer Cytopathol 2010;118:17-23.